Abstract
We have previously reported the role of miR-217 in anti-cancer drug-resistance. miRNA array and miRNA hybridization analysis predicted miR-30a-3p as a target of miR-217. miR-30a-3p and miR-217 formed a negative feedback loop and regulated the expression of each other. Ago1 immunoprecipitation and co-localization analysis revealed a possible interaction between miR-30a-3p and miR-217. miR-30a-3p conferred resistance to anti-cancer drugs and enhanced the invasion, migration, angiogenic, tumorigenic, and metastatic potential of cancer cells in CAGE-dependent manner. CAGE increased the expression of miR-30a-3p by binding to the promoter sequences of miR-30a-3p, suggesting a positive feedback loop between CAGE and miR-30a-3p. miR-30a-3p decreased the expression of p53, which showed the binding to the promoter sequences of miR-30a-3p and CAGE in anti-cancer drug-sensitive cancer cells. Luciferase activity assays showed that p53 serves as a target of miR-30a. Thus, the miR-30a-3p-CAGE-p53 feedback loop serves as a target for overcoming resistance to anti-cancer drugs.
References
Apr 2, 2002·Biochemical and Biophysical Research Communications·Bomsoo ChoDoo-Il Jeoung
Jul 10, 2003·Biochemical and Biophysical Research Communications·Bomsoo ChoDoo-Il Jeoung
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi IwataYutaka Kawakami
Mar 12, 2010·The Journal of Biological Chemistry·Elaine PorHanSoo Lee
Jun 11, 2010·The Journal of Biological Chemistry·Youngmi KimDooil Jeoung
Apr 14, 2012·The FEBS Journal·Weiwei ChengHui Wang
Feb 6, 2013·PloS One·Zhifan JiaPeiyu Pu
Jul 6, 2013·Cell Stem Cell·Su Jung SongPier Paolo Pandolfi
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brent N RexerCarlos L Arteaga
Sep 11, 2013·Cellular Signalling·Zhaolin ChenJun Li
Nov 1, 2013·The Journal of Biological Chemistry·Youngmi KimDooil Jeoung
Nov 6, 2013·Cancer Discovery·Lijoy K MathewM Celeste Simon
Dec 20, 2013·Cancer Science·Chie NishiokaAkihito Yokoyama
Jan 1, 2014·PloS One·Linda BojmarPer Sandström
Jan 23, 2014·Journal of Cellular and Molecular Medicine·Zhifang LiuJihui Jia
Feb 11, 2014·Biochemical and Biophysical Research Communications·Jing FuZhaohui Lv
Mar 19, 2014·PloS One·Luis G Pérez-RivasJosé Lozano
Apr 18, 2014·PloS One·Wei-xian ChenJin-hai Tang
May 9, 2014·Experimental Biology and Medicine·Hai-Yun WangJian-Yong Shao
Jul 30, 2014·Molecular and Cellular Endocrinology·Zhe Bao WuWei Guo Zhao
Aug 21, 2014·The Journal of Biological Chemistry·Youngmi KimDooil Jeoung
Aug 21, 2014·Journal of Neuro-oncology·Wanghao ChenQiaoyu Li
Sep 23, 2014·Molecules and Cells·Junhua GuoWujie Lu
Oct 7, 2014·Journal of Cellular and Molecular Medicine·Cuiping MaoChangjun Lv
Oct 17, 2014·British Journal of Cancer·P ChaudharyJ K Vishwanatha
Dec 17, 2014·Breast Cancer Research : BCR·Kyung-min LeeIncheol Shin
Citations
Aug 31, 2018·Journal of Oncology·Lin-Hong JiangJin-Hai Tang
Apr 19, 2018·Cell Death and Differentiation·Alessandra di GennaroRoberta Maestro
Jun 8, 2017·BMC Medical Genomics·Manu ShivakumarDokyoon Kim
Apr 7, 2020·Cell Death & Disease·Wei ChenYing Dong
Jun 3, 2021·Current Oncology·Ye-Rin KimSang-Yull Lee